1080 results about "Drug development" patented technology

A scalable platform for orchestrating networks of specialized AI multi-agent networks that enables secure collaboration through token-based protocols and real-time result streaming with advanced dynamic chain-of-thought pruning. The central orchestration engine manages domain-specific agents, implementing sophisticated multi-branch reasoning with contribution-estimation layers that evaluate each agent's utility using Shapley value-inspired metrics. The system employs information-theoretic and gradient-based surprise metric to guide memory updates and dynamic reasoning expansion, preventing local minima stagnation while preserving valuable insights through adaptive forgetting mechanisms. The platform unifies Monte Carlo tree search with contribution-aware estimation to detect high-synergy expert combinations while maintaining privacy through partial data approaches. It scales across distributed computing environments, enabling complex collaborative tasks like materials discovery, product engineering and manufacturing process design, biomedical research, and drug development. The system supports multi-party economic rewards through systematic contribution effort, cost and importance tracking, while standardized interfaces manage security, privacy, and policy constraints across heterogeneous agents.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The invention relates to the technical field of computer-aided drug research and development, and provides an antibacterial peptide function recognition optimization method and system based on deep learning and LLM. Systematic innovation is performed in multiple links such as feature extraction, data generation and reasoning verification by introducing a fusion mechanism of a large language model and a deep learning model; and the accuracy and robustness of antibacterial peptide function prediction are obviously improved. On one hand, a strict feature extraction process and a structured cue word template are constructed, sequence information and physicochemical property indexes of the antibacterial peptide and a prediction result of a deep learning model can be effectively integrated, and the prediction result is reasonably corrected and optimized through the reasoning ability and knowledge verification mechanism of a large language model. The misjudgment risk of a traditional deep learning method under the condition of insufficient samples or incomplete features is effectively reduced, and the prediction accuracy and stability are remarkably improved.

The invention discloses a multi-dimensional screening method for protein design based on a lexicographical order optimization strategy, and belongs to the field of biotechnology and synthetic biology. The method comprises the following steps: predicting a three-dimensional structure of a compound of a target protein and a ligand to construct a three-dimensional skeleton model of the target protein; generating a functional adaptive amino acid sequence; and adopting multi-dimensional screening indexes, including structure prediction precision, thermodynamic stability evaluation, thermal stability analysis and physicochemical property calculation, and performing priority ranking and hierarchical screening on candidate sequences in combination with a lexicographical order optimization algorithm. Through strict priority-driven multi-objective optimization, the design efficiency and success rate are remarkably improved, the number of experimental verification times is reduced, and the method is suitable for the fields of drug development, industrial enzyme engineering, gene therapy and the like and has important application value.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The application provides a Huangdache oligosaccharide with GLP-1 agonist activity and application thereof, and belongs to the technical field of medicines. 3 The oligosaccharide component ELYP-3 has a molecular weight of 3.2*10 3 Da, and the molar ratio of monosaccharides is rhamnose:galacturonic acid:glucose:galactose:arabinose = 1:32.42:45.37:9.11:6.54. The Huangdache oligosaccharide fragment obtained by glycosidase degradation has significant hypoglycemic and weight loss activities, the preparation process is simple, specific and green, and provides scientific basis and theoretical support for the development of natural GLP-1 agonists. Meanwhile, the functional oligosaccharide provides a wide application prospect for the development of medicines with blood glucose regulation.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The present invention provides a tetrazole compound, a pharmaceutical composition thereof and a use thereof. The compound of the present invention has a brand-new structure, a low clearance rate, high plasma exposure, good oral bioavailability, and good pharmacokinetic properties, and is conducive to drug development. The compound of the present invention or a pharmaceutically acceptable salt thereof can be used for preventing and / or treating pain, including neuropathic pain, etc.

The invention belongs to the technical field of drug development, and particularly relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of a medicine for treating nervous system diseases. It is proved that the compound 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

An application method of a modified peptide derived from Urechis unicinctus is to prepare a drug for treating alcoholic liver disease. The modified peptide derived from Urechis unicinctus is one or more selected from F2-1: IHVKF (SEQ ID NO: 1), F2-2: VHFKI (SEQ ID NO: 2), F4-1: GAWKP (SEQ ID NO: 3), F4-2: AGWKP (SEQ ID NO: 4), F5-1: GTLKP (SEQ ID NO: 5), F5-2: GTPKL (SEQ ID NO: 6), F7-1: IIVRM (SEQ ID NO: 7), and F7-2: IRMVI (SEQ ID NO: 8). The modified peptide derived from Urechis unicinctus can enhance the degradation of alcohol and boost the survival rate of cells with alcoholic liver disease, and also alleviate lipid metabolism and inflammation in mice, protecting liver from alcoholic liver disease. When applied in drug development for treating alcoholic liver disease, the application method offers low-risk, low-cost, and is simple to operate therapeutic options.

The invention discloses application of PGRN in preparation of products for preventing and treating neuropsychiatric disorder related diseases caused by estrogen deficiency. The invention provides an application of a PGRN protein or a coding gene thereof or a virus expressing the coding gene thereof in preparation of a product with any one of the following functions: 1) preventing or treating or saving neuropsychiatric disorder related diseases caused by estrogen deficiency; 2) preventing or treating perimenopausal anxiety and / or depression symptoms; and 3) relieving anxiety-like behaviors and / or depression-like behaviors caused by estrogen deficiency. The application proves that the PGRN can play a role in protecting neuron damage caused by estrogen deficiency by rescuing CTSD enzyme activity and an autophagy pathway, and prompts that related medicines and measures influencing secretion and content of the PGRN can treat perimenopausal anxiety and depressive symptoms; and a new target and a new idea are provided for clinical treatment and drug development of anxiety and depression symptoms of climacteric women.

The invention discloses a chemical reaction large language model training method and a synthetic path planning method, and belongs to the technical field of chemical information artificial intelligence. According to the method, a chemical reaction is expressed as a reaction sentence in an SMILES format, a digital sequence is generated by using a token taking atoms, punctuation marks, numbers and the like as units, and mask filling self-supervision pre-training is carried out by adopting a large language model based on a Transform architecture, so that a chemical reaction rule is learned. In combination with a Monte Carlo tree search algorithm, performing multi-step inverse synthesis path planning on the target molecule, and outputting strategy probability and value estimation; and through multi-task fine tuning, molecular property classification, reaction condition regression and process parameter complementation are supported. The method improves the chemical reaction modeling efficiency and the intelligent level of synthesis path planning, and is suitable for the fields of new drug research and development, material discovery and the like.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention relates to the technical field of drug safety evaluation, in particular to a multi-center combined evaluation method and system for drug safety based on a graph neural network and federated learning. Known and unknown drug interaction is systematically predicted based on a drug multi-relation knowledge graph and a graph neural network, a key path of DDI is identified through a graph attention mechanism, a molecular mechanism of the interaction is revealed, and natural language interpretation is generated. And meanwhile, through privacy protection and multi-center cooperation, a federal learning architecture is utilized to break data islands and improve the external effectiveness of an evaluation conclusion on the premise of protecting patient privacy and meeting data compliance requirements. The heterogeneity of data of different mechanisms is effectively evaluated through distribution deviation detection, deviation caused by blind extrapolation is avoided, a real-world evidence methodology report and a data traceability auditing clue are automatically generated, the requirement of a supervision mechanism for real-world evidence quality is met, medicine supervision decision is supported, and medicine research, development and review are accelerated.

The invention provides a system for designing and optimizing D-type biomolecules and a method and application thereof. The system comprises a stereoisomerization conversion module, a conjugate skeleton generation module, a sequence design module and an optimization module. The method comprises the following steps: firstly, carrying out stereoisomerization conversion on a target protein structure to generate a stereoisomer structure, and generating a constrained conjugate by utilizing a modeling algorithm under the structural constraint of the stereoisomer structure; on the basis of the generated conjugate skeleton, predicting an adaptive amino acid sequence, and then performing stereoisomerization conversion to obtain the corresponding D-type biomolecule conjugate. And meanwhile, an evolutionary Bayesian optimization algorithm is adopted to carry out iterative optimization on the biomolecule sequence. According to the method, structural constraint and an advanced optimization algorithm are fully utilized, efficient design and optimization of the D-type biomolecules are achieved, high universality and expandability are achieved, and a powerful tool is provided for drug development and biotechnology research.

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.

The invention discloses a meta-learning-based small sample pharmacokinetic property prediction method and related equipment, and relates to the field of pharmacokinetics. The method comprises the following steps: acquiring multi-dimensional feature data of candidate compounds, wherein the multi-dimensional feature data comprises atomic-scale features, molecular descriptors and molecular structure features; inputting the multi-dimensional feature data into a preset pharmacokinetic property prediction model to obtain a preliminary prediction result, the pharmacokinetic property prediction model being pre-trained through meta-learning based on small samples, the model comprising a first machine learning model and a second machine learning model, the preliminary prediction result comprises a first prediction result output by the first machine learning model and a second prediction result output by the second machine learning model; and determining a pharmacokinetic property prediction result of the candidate compound according to the first prediction result and the second prediction result. According to the method, the problem of low accuracy of a pharmacokinetic property prediction result can be relieved in a small sample scene of early drug research and development.

The invention discloses a fungal effect protein prediction model based on a protein language model and deep learning, and relates to the technical field of bioinformatics and deep learning, and the method comprises the steps: 1, collecting fungal effect protein data and non-effect protein data; 2, obtaining protein embedding through a protein language model; 3, performing oversampling processing on the data; 4, constructing a deep learning model; 5, model training; and 6, performing cross validation and independent test evaluation. According to the invention, a geometric oversampling technology (G-SMOTE) is adopted to carry out oversampling processing, so that the problem of sample imbalance is solved; a protein language model is adopted to obtain protein embedding characteristics to strengthen protein expression; and the prediction accuracy is improved by using a deep learning model architecture. The method can be applied to agricultural disease prevention and control, drug development and biotechnology research, important support is provided for identification and research of fungal effect protein, prediction accuracy can be improved, dependence on expensive experiments is reduced, and labor cost is reduced.

The invention belongs to the technical field of drug development, and particularly relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of a medicine for treating nervous system diseases, in particular to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide. It is proved that the compound (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention relates to the technical field of molecular biology, gene therapy and drug development, and provides application of TRIM44 as a target in preparation of a drug for treating non-alcoholic fatty liver. The medicine prevents, relieves and / or treats the non-alcoholic fatty liver disease by inhibiting the expression level of TRIM44. According to the application disclosed by the invention, the TRIM44 is taken as a target, and the non-alcoholic fatty liver is prevented, relieved and treated by reducing the expression level of the TRIM44. The TRIM44 inhibitor enables the liver weight and the proportion of the liver in the body weight of a patient to be remarkably reduced, lipid accumulation to be reduced, fat deposition and vacuolation degree of liver tissue to be reduced and liver texture to be improved under poor diet conditions of high fat, high sugar and the like, so that the non-alcoholic fatty liver is prevented, relieved and treated, and the health state of the patient is improved.

The invention belongs to the technical field of experimental zoology, and particularly relates to a gastric cancer precancerous lesion animal model and a construction method and application thereof. The construction method of the gastric precancerous lesion animal model comprises the following steps that a modeling animal freely drinks a modeling agent solution every day for modeling, and the concentration of the modeling agent solution is increased in a gradient mode within 200 mg / L-800 mg / L along with the modeling time. The gastric cancer precancerous lesion animal model is constructed by the method. The gastric precancerous lesion animal model is applied to screening, research and development of traditional Chinese medicines for treating gastric precancerous lesions including chronic atrophic gastritis, intestinal metaplasia and dysplasia. The method can solve the technical problem that the existing gastric precancerous lesion animal model construction method cannot accurately simulate the disease stage evolution, can simply, conveniently and efficiently construct the gastric precancerous lesion model, and has important meanings for scientific research verification, drug research and development, quality control, clinical application and the like of traditional Chinese medicines or formulae for treating gastric precancerous lesions.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention discloses bifidobacterium longum B14 with efficient lactose degradation capability and low gas production characteristic and application of the bifidobacterium longum B14, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium longum B14 is GDMCC No: 67276. The bifidobacterium longum B14 strain provided by the invention can effectively decompose lactose in intestinal tracts, meanwhile, uncomfortable symptoms such as abdominal distension caused by gas production are reduced to the maximum extent, and the technical problem that in the prior art, an efficient lactose degradation strain and the low gas production characteristic are difficult to consider at the same time is successfully solved. The invention provides a core strain resource for developing probiotic products capable of relieving main symptoms of lactose intolerance and remarkably reducing side effects. The strain has a definite application prospect and a remarkable industrial value in development of health care products and medicines.

The invention discloses a culture medium composition for culturing GDT cells and a culture method, and belongs to the field of biological medicine. Aiming at the problems of low in-vitro amplification efficiency and poor function of the existing GDT cells, the invention provides the culture medium composition for culturing the GDT cells, the culture medium composition comprises an induction culture medium and a proliferation culture medium, the induction culture medium comprises a basic culture medium and an activating agent, and the activating agent comprises IL-7 and paclitaxel; the proliferation culture medium comprises a basic culture medium, IL-18 and a metabolism regulator. An STAT5 pathway is activated through IL-7, and amplification of the Vdelta2 subgroup is specifically promoted; on the other hand, through the cooperation of the IL-7 and the IL-18, the IL-18 activates the expression of the NKG2D, and the IL-18 and the IL-7 jointly enhance the cytotoxicity; efficient amplification and function enhancement of the GDT cells are achieved; the killing rate of PD-L1 + tumor cells is larger than 80%, the motility rate after cryopreservation recovery is larger than 90%, the function maintenance rate is larger than 85%, and the cell line is suitable for tumor immunotherapy, infectious disease treatment and cell drug development.

The invention discloses a degradation agent based on indole group fusion covalent warheads and a preparation method and application thereof, and relates to the technical field of drug development, the structural formula of the degradation agent is as follows: R is a single bond or-NH-; a single bond, a, a, a, or a; and is-NH-, or; or; r1 and R2 are respectively and independently-H,-F,-Cl,-Br,-CH3,-OCH3,-NO2,-CH2-O-Ph or-CN; ph is phenyl; and a connection site is represented. According to the invention, an E3 ubiquitin ligase ligand is constructed by using an indole skeleton and acrylate, and then the E3 ubiquitin ligase ligand is connected with a BRD4 protein inhibitor JQ1 through a linker, so that a series of degradation agents based on indole group fusion covalent warheads are obtained, and targeted degradation of BRD4 protein is realized while an E3 ubiquitin ligase ligand library and a protein degradation targeted chimera molecular library are enriched.

The invention discloses an application of morchella enzymolysis polysaccharide in regulating lipid metabolism disorder. The morchella enzymolysis polysaccharide disclosed by the invention can be used for regulating lipid metabolism disorder, regulating intestinal flora and preventing liver injury, oxidative stress and inflammation. The morchella esculenta adopted by the invention is medicinal and edible morchella esculenta, is free of chemical modification and is high in safety; and the enzymolysis process is low in cost, easy to scale and suitable for functional food or medicine development. In addition, the invention provides the application value of 8-aminooctanoic acid as a lipid metabolism disorder marker for the first time, and expands the application scene of EMIP in preparation of diversified products for regulating intestinal flora, improving liver injury, reducing oxidative stress and the like.